FDA Sets ENCELTO Review Period for Patent Padding
Published Date: 4/3/2026
Notice
Summary
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
FDA sets ENCELTO review period
The FDA determined ENCELTO's regulatory review period is 7,903 days in total — 7,581 days in the testing phase and 322 days in the approval phase. The key dates are: IND effective July 18, 2003; BLA submitted April 18, 2024; BLA approved March 5, 2025. This determination establishes the maximum potential length of a patent extension, and the applicant is seeking 950 days of patent term extension.
Deadlines to challenge dates or diligence
Anyone who believes the published dates are wrong may submit comments and ask FDA for a redetermination by June 2, 2026 (electronic filing accepted until 11:59 p.m. ET that day). Any interested person may petition FDA about whether the applicant acted with due diligence during the regulatory review period by September 30, 2026.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in